In this study, we generated new in-vivo treatment models of Brca1- and Bard1-mutant breast cancer that recapitulate the striking response to PARPi, acquired resistance, and recurrence that is observed in patients with breast cancer. This evidence concerns the gene BRCA1 and breast carcinoma.